Canaccord Genuity Raises Doximity Price Target To $67, Maintains Hold

Canaccord Genuity raised its price target on Doximity Inc. (NYSE: DOCS) to $67 from $59 while reiterating a Hold rating.

The firm noted that the rapid pace of change in the large language model (LLM) environment is reshaping healthcare technology. While scale and user adoption remain important, analysts said trust among users is critical to long-term success.

Doximity's position in the early stages of the AI transition could allow it to become one of the winners in the space, according to the firm. However, at current valuation levels, Canaccord maintained its Hold stance despite the raised target.